1 40 2 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.5688/aj7206s5" target="_blank" rel="noreferrer noopener">http://doi.org/10.5688/aj7206s5</a> Pages 1–17 Issue 6 Volume 72 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Report of the 2007-2008 Professional Affairs Committee. Publisher An entity responsible for making the resource available American journal of pharmaceutical education Date A point or period of time associated with an event in the lifecycle of the resource 2008 2008-12 Creator An entity primarily responsible for making the resource Robinson Daniel C; Chesnut Renae J; Copeland Debra A; Dawson Karan N; Haines Stuart T; Jastram Charles W; McGory Robb; Romanelli Frank; Tahir Rabia; Flynn Arlene A Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.5688/aj7206s5" target="_blank" rel="noreferrer noopener">10.5688/aj7206s5</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2008 American journal of pharmaceutical education Chesnut Renae J Copeland Debra A Dawson Karan N Flynn Arlene A Haines Stuart T Jastram Charles W McGory Robb Robinson Daniel C Romanelli Frank Tahir Rabia Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1111/j.1478-3231.2010.02295.x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1111/j.1478-3231.2010.02295.x</a> Pages 1103–1114 Issue 8 Volume 30 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Resveratrol and liver disease: from bench to bedside and community. Publisher An entity responsible for making the resource available Liver international : official journal of the International Association for the Study of the Liver Date A point or period of time associated with an event in the lifecycle of the resource 2010 2010-09 Subject The topic of the resource Acetaminophen/metabolism; Anti-Inflammatory Agents; Antioxidants/therapeutic use; Carbon Tetrachloride/metabolism; Cytokines/metabolism; Ethanol/metabolism; Free Radicals/metabolism; Glutathione/metabolism; Hepatocytes/drug effects/pathology; Humans; Liver Diseases/*drug therapy/epidemiology; NF-kappa B/antagonists & inhibitors; Non-Steroidal/therapeutic use; Resveratrol; Stilbenes/pharmacokinetics/*pharmacology/therapeutic use/toxicity Creator An entity primarily responsible for making the resource Bishayee Anupam; Darvesh Altaf S; Politis Themos; McGory Robb Description An account of the resource Liver diseases incorporate several maladies, which can range from benign histological changes to serious life-threatening conditions. These may include inborn metabolic disease, primary and metastatic cancers, alcoholic cirrhosis, viral hepatitis and drug-induced hepatotoxicity. Liver disease remains a major cause of morbidity and mortality with significant economic and social costs. Several novel approaches are currently being studied which may provide a better therapeutic outcome. The use of naturally occurring phytochemicals, some of them obtained from dietary sources, in the amelioration of illness have recently gained considerable popularity. These agents, having anti-oxidant and anti-inflammatory properties, provide a safe and effective means of ameliorating chronic disease. Resveratrol, a grape polyphenol, has shown considerable promise as a therapeutic agent in the treatment of the aforementioned liver ailments. Several studies have highlighted the hepatoprotective properties of resveratrol. Resveratrol has been shown to prevent hepatic damage because of free radicals and inflammatory cytokines, induce anti-oxidant enzymes and elevate glutathione content. Resveratrol has also been shown to modulate varied signal transduction pathways implicated in liver diseases. This review critically examines the current preclinical in vitro and in vivo studies on the preventive and therapeutic effects of resveratrol in liver diseases. The review highlights the pharmacological mechanisms involved in mediating the aforementioned effects. Toxicity, pharmacokinetics and clinical bioavailability of resveratrol are also reviewed in this article. The challenges involved, future directions and novel approaches such as site-specific drug delivery in the use of resveratrol for the prevention and treatment of liver disease are also discussed. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1111/j.1478-3231.2010.02295.x" target="_blank" rel="noreferrer noopener">10.1111/j.1478-3231.2010.02295.x</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). 2010 Acetaminophen/metabolism Anti-Inflammatory Agents Antioxidants/therapeutic use Bishayee Anupam Carbon Tetrachloride/metabolism Cytokines/metabolism Darvesh Altaf S Department of Pharmaceutical Sciences Ethanol/metabolism Free Radicals/metabolism Glutathione/metabolism Hepatocytes/drug effects/pathology Humans Liver Diseases/*drug therapy/epidemiology Liver international : official journal of the International Association for the Study of the Liver McGory Robb NEOMED College of Pharmacy NF-kappa B/antagonists & inhibitors Non-Steroidal/therapeutic use Politis Themos Resveratrol Stilbenes/pharmacokinetics/*pharmacology/therapeutic use/toxicity